| Literature DB >> 27839692 |
Kimie Sai1, Kouji Kajinami2, Hironobu Akao2, Mizuho Iwadare2, Ryoko Sato-Ishida2, Yasuyuki Kawai2, Kenji Takeda2, Takashi Tanimoto3, Takashi Yamano3, Takashi Akasaka3, Tatsuro Ishida4, Ken-Ichi Hirata4, Keijiro Saku5, Shusuke Yagi6, Takeshi Soeki6, Masataka Sata6, Masafumi Ueno7, Shunichi Miyazaki7, Aya Shiraki8, Jun-Ichi Oyama8, Koichi Node8, Koichi Sugamura9, Hisao Ogawa9, Kouichi Kurose10, Keiko Maekawa10, Yumiko Matsuzawa10, Takuya Imatoh10, Ryuichi Hasegawa10, Yoshiro Saito10.
Abstract
Statin-related myopathy (SRM) is a clinically important adverse reaction. Recent pharmacogenetic research, mainly in non-Asian populations, have indicated clinical relevance of some of genetic biomarkers to SRM, but predictive markers for SRM in Asian populations including Japanese has not yet been established. This study was aimed to identify clinically important genetic markers associated with SRM in Japanese patients. Allele frequencies of the three reported candidate markers - SLCO1B1 rs4149056, RYR2 rs2819742, and GATM rs9806699 - and carrier frequencies of HLA types were compared between patients with SRM patients (n = 52) and healthy Japanese subjects (n = 2878 or 86 (for rs9806699) as controls). No significant association of RYR2, SLCO1B1, and GATM variants with SRM were observed in our Japanese patients, but a significant association was detected for HLA-DRB1*04:06 with SRM (odds ratio: 3.19; 95% confidence interval: 1.53-6.66). This study suggested that HLA-DRB1*04:06 might be associated with SRM onset in a Japanese population. Further studies are required to validate these results.Entities:
Keywords: Genetic polymorphism; HLA; Myopathy; Rhabdomyolysis; Statin
Mesh：
Substances：
Year: 2016 PMID： 27839692 DOI： 10.1016/j.dmpk.2016.09.002
Source DB: PubMed Journal: Drug Metab Pharmacokinet ISSN： 1347-4367 Impact factor: 3.614